MTAP欠損進行性/転移性固形腫瘍患者におけるPRMT5阻害剤AZD3470の研究

基本情報

NCT ID: NCT06130553
ステータス: 募集中
試験のフェーズ: 第1/第2相
試験タイプ: 介入
目標被験者数: 234
治験依頼者名: AstraZeneca

概要

This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several study modules, evaluating the safety, tolerability, pharmacokinetic (PK), pharmacodynamics, and preliminary efficacy of AZD3470 as monotherapy or in combination with other anti-cancer agents.

対象疾患

Advanced Solid Tumors That Are MTAP Deficient

介入

AZD3470(DRUG)

依頼者（Sponsor）

アストラゼネカ株式会社(INDUSTRY)